MedTrace Logo

Sexual Effects of Transdermal or Vaginal Testosterone

NCT06794346 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2025-01-27

No results posted yet for this study

Summary

The aim of the study is to elucidate the role of testosterone treatment in postmenopausal women's sexual function and their therapeutic safety.

Conditions

  • Female Sexual Dysfunction
  • Postmenopausal Symptoms
  • Testosterone Deficiency
  • Testosterone Adverse Reaction

Interventions

DRUG

Transdermal testosterone

women will receive 300mcg of transdermal testosterone in cream daily for six months

DRUG

Vaginal testosterone gel

women will receive 300mcg of vaginal gel testosterone daily for six months

DEVICE

Placebo group

women will receive both vaginal gel and transdermal cream placebo for six months

Sponsors & Collaborators

  • University of Sao Paulo General Hospital

    lead OTHER

Principal Investigators

  • Edmund C Baracat, Head · University of Sao Paulo General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
38 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2024-10-01
Completion
2025-11-01

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06794346 on ClinicalTrials.gov